HRP20110556T1 - Novi postupci - Google Patents
Novi postupci Download PDFInfo
- Publication number
- HRP20110556T1 HRP20110556T1 HR20110556T HRP20110556T HRP20110556T1 HR P20110556 T1 HRP20110556 T1 HR P20110556T1 HR 20110556 T HR20110556 T HR 20110556T HR P20110556 T HRP20110556 T HR P20110556T HR P20110556 T1 HRP20110556 T1 HR P20110556T1
- Authority
- HR
- Croatia
- Prior art keywords
- aclidinium
- patient
- use according
- condition
- disease
- Prior art date
Links
- ASMXXROZKSBQIH-VITNCHFBSA-N aclidinium Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 ASMXXROZKSBQIH-VITNCHFBSA-N 0.000 claims abstract 16
- 229940019903 aclidinium Drugs 0.000 claims abstract 15
- 208000023504 respiratory system disease Diseases 0.000 claims abstract 7
- 230000002265 prevention Effects 0.000 claims abstract 4
- 230000001022 anti-muscarinic effect Effects 0.000 claims abstract 2
- 230000009885 systemic effect Effects 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010010774 Constipation Diseases 0.000 claims 2
- 239000000808 adrenergic beta-agonist Substances 0.000 claims 2
- 229940125715 antihistaminic agent Drugs 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 claims 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010051482 Prostatomegaly Diseases 0.000 claims 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims 1
- 206010038678 Respiratory depression Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000001871 Tachycardia Diseases 0.000 claims 1
- 206010043521 Throat irritation Diseases 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 206010047513 Vision blurred Diseases 0.000 claims 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 1
- 229960004373 acetylcholine Drugs 0.000 claims 1
- 229960005012 aclidinium bromide Drugs 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 1
- 229940127236 atypical antipsychotics Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 230000030135 gastric motility Effects 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 210000001747 pupil Anatomy 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 230000035900 sweating Effects 0.000 claims 1
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Aklidinium, za upotrebu u liječenju ili prevenciji respiratorne bolesti ili stanja kod pacijenta putem inhalacije, naznačen time, što pacijent boluje ili je podložan stanju koje može biti pogoršano sustavnom antimuskarinskom aktivnošću. Patent sadrži još 12 patentnih zahtjeva.
Claims (13)
1. Aklidinium, za upotrebu u liječenju ili prevenciji respiratorne bolesti ili stanja kod pacijenta putem inhalacije, naznačen time, što pacijent boluje ili je podložan stanju koje može biti pogoršano sustavnom antimuskarinskom aktivnošću.
2. Aklidinium, za upotrebu prema patentnom zahtjevu 1, naznačen time, što je respiratorna bolest ili stanje izabrano iz akutnog ili kroničnog bronhitisa, emfizema, astme i kronične opstruktivne plućne bolesti, naročito astme i kronične opstruktivne plućne bolesti.
3. Aklidinium, za upotrebu prema bilo kojem prethodnom patentnom zahtjevu naznačen time, što pacijent boluje ili je podložan jednom ili više izabranih iz
i. shizofrenija, smanjena koncentracija, konfuzija, agitacija, delirija, nedostatak pažnje, oslabljena memorija, respiratorna depresija,
ii. glaukom, suhoća oka, povećana veličina zjenice, zamagljen vid, povišen intraokularni tlak,
iii. povećana prostata ili njena opstrukcija, poteškoće pri mokrenju,
iv. suženje ili opstrukcija tankog crijeva, povećano debelo crijevo, kronični zatvor, povećani donji mišić jednjaka, smanjena želučana pokretljivost, zatvor,
v. suha usta, iritacija grla, smanjeno znojenje,
vi. kardiovaskularna bolest (uključujući bilo koju restenoza, arterioskleroza, raniji moždani udar ili srčani udar, kongestivno zatajenje srca), aritmija, tahikardija,
vii. Parkinsonova bolest, Alzheimerova bolest, demencija, i
viii. miastenija gravis.
4. Aklidinium za upotrebu prema bilo kojem prethodnom patentnom zahtjevu naznačen time, što
pacijent je muško, i / ili
pacijent je stariji od šezdeset godina, i / ili
pacijent namjerava voziti ili upravljati strojevima tijekom trajanja liječenja i / ilipacijent prima drugi lijek koji je sustavno aktivni antiholinergični agens, ili agens koji može uzrokovati ili pogoršati bilo koje stanje definirano u patentnom zahtjevu 3, pri čemu je poželjno da je taj drugi lijek izabran iz atipičnih antipsihotika, tricikličkih antidepresiva i antihistaminika.
5. Aklidinium, za upotrebu prema patentnom zahtjevu 4, naznačen time, što pacijent prima lijek koji je namijenjen za povećanje funkcije acetilkolina.
6. Aklidinium, za upotrebu prema bilo kojem prethodnom patentnom zahtjevu, naznačen time, što je aklidinium u obliku aklidinium bromida.
7. Aklidinium, za upotrebu prema bilo kojem prethodnom patentnom zahtjevu, naznačen time, što je aklidinium u obliku suhog praha pogodnog za inhalaciju.
8. Aklidinium, za upotrebu prema bilo kojem prethodnom patentnom zahtjevu, naznačen time, što pacijent prima jedan ili više dodatnih lijekova za liječenje respiratorne bolesti ili stanja.
9. Aklidinium, za upotrebu prema patentnom zahtjevu 8, naznačen time, što je dodatni lijek za liječenje respiratorne bolesti ili stanja izabran iz beta-adrenergičkih agonista, kortikosteroida ili glukokortikoida, inhibitora PDE IV, antihistamina, anti-IgE protutijela, inhibitora leukotriena D4, inhibitora egfr-kinaze, inhibitora p38 kinaze i / ili agonista NK1 receptora.
10. Aklidinium, za upotrebu prema patentnom zahtjevu 9, naznačen time, što je dodatni lijek izabran iz kortikosteroida i / ili beta-adrenergičkih agonista.
11. Upotreba aklidiniuma, naznačena time, što je definirano u bilo kojem od patentnih zahtjeva 1, 6 i 7, u proizvodnji lijeka, za upotrebu u liječenju ili prevenciji, putem inhalacije, respiratorne bolesti ili stanja kao što je definirano u patentnom zahtjevu 1 ili 2, kod pacijenta kao što je definirano u bilo kojem od patentnih zahtjeva 1, 3 do 5 i 8 do 10.
12. Farmaceutski pripravak naznačen time, što za upotrebu kod liječenja ili prevencije, putem inhalacije, respiratorne bolesti ili stanja kao što je definirano u patentnom zahtjevu 1 ili 2, kod pacijenta kao što je definirano u bilo kojem patentnom zahtjevu 1, 3 do 5 i 8 do 10, koji farmaceutski pripravak sadrži farmaceutski prihvatljiv nosač i, kao aktivni sastavni dio, aklidinium, kao što je definirano u bilo kojem od patentnih zahtjeva 1, 6 i 7.
13. Farmaceutski pripravak za upotrebu prema patentnom zahtjevu 12, naznačen time, što je farmaceutski prihvatljiv nosač izabran iz mono-, di- ili polisaharida i alkoholnog šećera, po mogućnosti laktoze.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90284307P | 2007-02-21 | 2007-02-21 | |
| PCT/EP2008/000782 WO2008101591A1 (en) | 2007-02-21 | 2008-01-31 | Novel methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110556T1 true HRP20110556T1 (hr) | 2011-09-30 |
Family
ID=39247776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110556T HRP20110556T1 (hr) | 2007-02-21 | 2011-07-26 | Novi postupci |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US20110243924A1 (hr) |
| EP (1) | EP2120936B1 (hr) |
| JP (2) | JP5739616B2 (hr) |
| KR (2) | KR20090114401A (hr) |
| CN (2) | CN101616670A (hr) |
| AR (1) | AR065392A1 (hr) |
| AT (1) | ATE513547T1 (hr) |
| AU (1) | AU2008217301B2 (hr) |
| BR (1) | BRPI0806392A8 (hr) |
| CA (1) | CA2678975C (hr) |
| CL (1) | CL2008000461A1 (hr) |
| CO (1) | CO6210814A2 (hr) |
| CY (1) | CY1111799T1 (hr) |
| DK (1) | DK2120936T3 (hr) |
| EC (1) | ECSP099556A (hr) |
| ES (1) | ES2367722T3 (hr) |
| HK (1) | HK1132673A1 (hr) |
| HR (1) | HRP20110556T1 (hr) |
| IL (1) | IL200278A (hr) |
| MX (1) | MX2009008825A (hr) |
| MY (1) | MY153408A (hr) |
| NZ (1) | NZ578473A (hr) |
| PE (1) | PE20081789A1 (hr) |
| PL (1) | PL2120936T3 (hr) |
| PT (1) | PT2120936E (hr) |
| RU (1) | RU2484821C2 (hr) |
| SI (1) | SI2120936T1 (hr) |
| TW (1) | TWI475994B (hr) |
| UA (1) | UA98136C2 (hr) |
| UY (1) | UY30901A (hr) |
| WO (1) | WO2008101591A1 (hr) |
| ZA (1) | ZA200904941B (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| CA2768553C (en) | 2009-08-07 | 2016-08-02 | Generics [Uk] Limited | Anhydrate of tiotropium bromide |
| WO2011095800A2 (en) * | 2010-02-02 | 2011-08-11 | Generics [Uk] Limited | Analytical methods |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| US20150202297A1 (en) * | 2012-07-05 | 2015-07-23 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhalers comprising a carrier other than lactose and a ternary component |
| US10105316B2 (en) | 2012-07-05 | 2018-10-23 | Arven llac Sanayi Ve Ticaret A.S. | Inhalation compositions comprising muscarinic receptor antagonist |
| US10111957B2 (en) | 2012-07-05 | 2018-10-30 | Arven Ilac Snayi ve Ticaret A.S. | Inhalation compositions comprising glucose anhydrous |
| US20200054611A1 (en) | 2017-01-09 | 2020-02-20 | Gt Biopharma, Inc. | Use and composition for treating myasthenia gravis and other myasthenic syndromes |
| WO2019023318A1 (en) * | 2017-07-25 | 2019-01-31 | Gt Biopharma, Inc. | PHARMACEUTICAL COMPOSITIONS AND METHODS USING PYRIDOSTIGMINE AND AN ANTAGONIST OF NK-1 FOR TREATING SEVERE MYASTHENIA |
| WO2019023175A1 (en) * | 2017-07-25 | 2019-01-31 | Gt Biopharma, Inc. | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE AND NEOSTIGMINE AND AN ANTAGONIST NK-1 FOR THE TREATMENT OF SEVERE MYASTHENIA |
| WO2020014072A1 (en) * | 2018-07-09 | 2020-01-16 | Gt Biopharma, Inc. | Neostigmine pharmaceutical combination for treating myasthenia gravis |
| EP3939585A4 (en) * | 2020-05-20 | 2022-03-02 | Syntekabio, Inc. | PREVENTIVE OR THERAPEUTIC COMPOSITION FOR INFECTIOUS DISEASES WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 |
| KR102169476B1 (ko) * | 2020-05-20 | 2020-10-23 | (주)신테카바이오 | 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물 |
| CN115267024B (zh) * | 2022-07-31 | 2023-06-30 | 浙江知一药业有限责任公司 | 治疗呼吸系统疾病的药物组合物及其检测方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) * | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US20050026948A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| DE102004016179A1 (de) | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Verbindungen zur Behandlung von proliferativen Prozessen |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
-
2008
- 2008-01-31 CN CN200880005871A patent/CN101616670A/zh active Pending
- 2008-01-31 CA CA2678975A patent/CA2678975C/en active Active
- 2008-01-31 NZ NZ578473A patent/NZ578473A/en unknown
- 2008-01-31 US US12/528,267 patent/US20110243924A1/en not_active Abandoned
- 2008-01-31 WO PCT/EP2008/000782 patent/WO2008101591A1/en active Application Filing
- 2008-01-31 ES ES08707469T patent/ES2367722T3/es active Active
- 2008-01-31 DK DK08707469.6T patent/DK2120936T3/da active
- 2008-01-31 PT PT08707469T patent/PT2120936E/pt unknown
- 2008-01-31 JP JP2009550665A patent/JP5739616B2/ja active Active
- 2008-01-31 EP EP08707469A patent/EP2120936B1/en active Active
- 2008-01-31 AT AT08707469T patent/ATE513547T1/de active
- 2008-01-31 MX MX2009008825A patent/MX2009008825A/es active IP Right Grant
- 2008-01-31 RU RU2009135078/15A patent/RU2484821C2/ru active
- 2008-01-31 UA UAA200909464A patent/UA98136C2/ru unknown
- 2008-01-31 KR KR1020097017243A patent/KR20090114401A/ko not_active Application Discontinuation
- 2008-01-31 PL PL08707469T patent/PL2120936T3/pl unknown
- 2008-01-31 CN CN201510633145.XA patent/CN105395548A/zh active Pending
- 2008-01-31 SI SI200830381T patent/SI2120936T1/sl unknown
- 2008-01-31 AU AU2008217301A patent/AU2008217301B2/en active Active
- 2008-01-31 BR BRPI0806392A patent/BRPI0806392A8/pt not_active Application Discontinuation
- 2008-01-31 KR KR20157007787A patent/KR20150038750A/ko not_active Application Discontinuation
- 2008-01-31 MY MYPI20093444A patent/MY153408A/en unknown
- 2008-02-07 UY UY0001030901A patent/UY30901A/es unknown
- 2008-02-13 CL CL200800461A patent/CL2008000461A1/es unknown
- 2008-02-20 AR ARP080100680A patent/AR065392A1/es unknown
- 2008-02-20 PE PE2008000361A patent/PE20081789A1/es not_active Application Discontinuation
- 2008-02-20 TW TW097105887A patent/TWI475994B/zh not_active IP Right Cessation
-
2009
- 2009-07-15 ZA ZA2009/04941A patent/ZA200904941B/en unknown
- 2009-08-04 EC EC2009009556A patent/ECSP099556A/es unknown
- 2009-08-06 IL IL200278A patent/IL200278A/en active IP Right Grant
- 2009-08-21 CO CO09088171A patent/CO6210814A2/es not_active Application Discontinuation
-
2010
- 2010-01-05 HK HK10100031.9A patent/HK1132673A1/xx unknown
-
2011
- 2011-07-26 HR HR20110556T patent/HRP20110556T1/hr unknown
- 2011-08-31 CY CY20111100836T patent/CY1111799T1/el unknown
-
2013
- 2013-12-05 JP JP2013252283A patent/JP2014062114A/ja active Pending
-
2014
- 2014-12-05 US US14/561,857 patent/US20150093374A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110556T1 (hr) | Novi postupci | |
| US11680044B2 (en) | Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine | |
| JP2008540672A (ja) | 病状に起因する性的機能不全の治療方法 | |
| CA2960611A1 (en) | Neuroactive steroids, compositions, and uses thereof | |
| JP2006523216A5 (hr) | ||
| CN107406422A (zh) | 作为sGC刺激剂的吡唑衍生物 | |
| JP2009536176A5 (hr) | ||
| CA3043028A1 (en) | Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions | |
| US20100160294A1 (en) | Tolerability of mirtazapine and a second active by using them in combination | |
| KR20210125507A (ko) | 수면성 무호흡의 치료 방법 및 조성물 | |
| US20090275562A1 (en) | Tolerability of mirtazapine and a second active by using them in combination | |
| JP2017526695A5 (hr) | ||
| JP5362151B2 (ja) | Ｐｇｄ２拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬 | |
| TW201039817A (en) | Pyrrolidine substituted flavones as radio sensitizers | |
| US20090048233A1 (en) | Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination | |
| WO2017073708A1 (ja) | 外用剤 | |
| CN106459066A (zh) | 治疗睡眠过度的方法 | |
| WO2016006621A1 (ja) | Ｐｇｄ２拮抗剤を含有するアレルギー性疾患に伴う症状の治療用医薬 | |
| JP5978471B2 (ja) | 耳鳴患者の治療用の薬剤 | |
| CN113692277B (zh) | 用于治疗睡眠呼吸暂停的方法和组合物 | |
| WO2015166918A1 (ja) | 耳鳴患者の治療用の薬剤 | |
| WO2020094592A1 (en) | Compounds for treating negative symptoms and cognitive impairments | |
| JPWO2007049732A1 (ja) | 関節リウマチの予防及び／又は治療法 | |
| CN107011337A (zh) | N‑[5‑(1,2,4‑三唑‑1‑基)噻唑‑2‑基]哌啶基酰胺及其医药用途 | |
| JP2019524860A5 (hr) |